{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Selected+Types+of+Solid+Tumor&page=2", "query": { "condition": "Selected Types of Solid Tumor", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 127, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Selected+Types+of+Solid+Tumor&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Selected+Types+of+Solid+Tumor&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-30T05:52:30.143Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00536601", "title": "High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Burkitt Lymphoma", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", "Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET)", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Peripheral T-cell Lymphoma", "Plasma Cell Neoplasm", "Primary Systemic Amyloidosis", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Neuroblastoma", "Recurrent Small Lymphocytic Lymphoma", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Multiple Myeloma", "Regional Neuroblastoma", "Splenic Marginal Zone Lymphoma", "Testicular Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific", "Unspecified Childhood Solid Tumor, Protocol Specific", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "etoposide", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "carmustine", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "busulfan", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "autologous hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "autologous-autologous tandem hematopoietic stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "ALL", "summary": "4 Years and older" }, "enrollment_count": 174, "start_date": "2006-06-29", "completion_date": "2018-07-09", "has_results": true, "last_update_posted_date": "2021-04-22", "last_synced_at": "2026-09-30T05:52:30.143Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00536601" }, { "nct_id": "NCT02663518", "title": "A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematologic Malignancies", "Solid Tumor" ], "interventions": [ { "name": "PF-0791800 (TTI-621)", "type": "DRUG" }, { "name": "PF-07901800 (TTI-621) plus Rituximab", "type": "DRUG" }, { "name": "PF-07901800 (TTI-621) plus Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 249, "start_date": "2016-01-28", "completion_date": "2022-11-23", "has_results": true, "last_update_posted_date": "2024-05-10", "last_synced_at": "2026-09-30T05:52:30.143Z", "location_count": 47, "location_summary": "Duarte, California • Palo Alto, California • Denver, Colorado + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02663518" }, { "nct_id": "NCT02601950", "title": "A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Rhabdoid Tumors (MRT)", "Rhabdoid Tumors of the Kidney (RTK)", "Atypical Teratoid Rhabdoid Tumors (ATRT)", "Selected Tumors With Rhabdoid Features", "Synovial Sarcoma", "INI1-negative Tumors", "Malignant Rhabdoid Tumor of Ovary", "Renal Medullary Carcinoma", "Epithelioid Sarcoma", "Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval)", "Any Solid Tumor With an EZH2 GOF Mutation" ], "interventions": [ { "name": "Tazemetostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Epizyme, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 267, "start_date": "2015-12-22", "completion_date": "2024-02-26", "has_results": true, "last_update_posted_date": "2025-06-22", "last_synced_at": "2026-09-30T05:52:30.143Z", "location_count": 14, "location_summary": "San Francisco, California • Aurora, Colorado • Jacksonville, Florida + 9 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02601950" }, { "nct_id": "NCT03478462", "title": "Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pediatric Solid Tumor", "Pediatric Lymphoma", "Pediatric Brain Tumor", "DIPG", "Neuroblastoma", "Ewing Sarcoma", "Rhabdomyosarcoma", "Osteosarcoma" ], "interventions": [ { "name": "CLR 131", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cellectar Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "2 Years to 25 Years" }, "enrollment_count": 30, "start_date": "2019-04-30", "completion_date": "2027-02-25", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-09-30T05:52:30.143Z", "location_count": 6, "location_summary": "Palo Alto, California • New York, New York • Chapel Hill, North Carolina + 3 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03478462" }, { "nct_id": "NCT02437916", "title": "Safety Study of AMG 228 to Treat Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignancy", "Advanced Solid Tumors", "Cancer", "Oncology", "Oncology Patients", "Tumors", "Melanoma", "Non-small Cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Transitional Cell Carinoma of Bladder", "Colorectal Cancer" ], "interventions": [ { "name": "AMG 228", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2015-04-21", "completion_date": "2016-12-12", "has_results": false, "last_update_posted_date": "2022-11-08", "last_synced_at": "2026-09-30T05:52:30.143Z", "location_count": 3, "location_summary": "La Jolla, California • New Haven, Connecticut • New York, New York", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02437916" }, { "nct_id": "NCT00585845", "title": "Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Epithelial Mesothelioma", "Adenocarcinoma of the Pancreas", "Carcinoma, Non-Small-Cell Lung", "Adenocarcinoma of the Ovaries" ], "interventions": [ { "name": "CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Anza Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2007-12", "completion_date": "2009-02", "has_results": false, "last_update_posted_date": "2009-02-20", "last_synced_at": "2026-09-30T05:52:30.143Z", "location_count": 3, "location_summary": "Baltimore, Maryland • Bethesda, Maryland • Philadelphia, Pennsylvania", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00585845" }, { "nct_id": "NCT03991741", "title": "Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Melanoma", "Locally Advanced Refractory/Recurrent Melanoma", "Metastatic Head and Neck Cancer", "Locally Advanced Refractory/Recurrent Head and Neck Cancer" ], "interventions": [ { "name": "Autologous Tumor Infiltrating Lymphocytes", "type": "BIOLOGICAL" }, { "name": "High-Dose Interleukin 2", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Gregory Daniels", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2020-10-07", "completion_date": "2023-01-26", "has_results": true, "last_update_posted_date": "2025-07-03", "last_synced_at": "2026-09-30T05:52:30.143Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03991741" }, { "nct_id": "NCT06427941", "title": "A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Hepatocellular Carcinoma", "Local Advanced Hepatocellular Carcinoma", "Alpha-fetoprotein (AFP)-Producing Gastric Cancer", "Extragonadal Yolk Sac Tumors", "Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer" ], "interventions": [ { "name": "BGB-B2033", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 630, "start_date": "2024-07-23", "completion_date": "2028-10-31", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-09-30T05:52:30.143Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Duarte, California + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Zion", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06427941" }, { "nct_id": "NCT04242199", "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "MSI-H/dMMR Tumors", "Cutaneous Squamous Cell Carcinoma", "Urothelial Carcinoma", "Cervical Cancer", "HepatoCellular Carcinoma", "Esophageal Squamous Cell Carcinoma", "Merkel Cell Carcinoma", "Small-cell Lung Cancer", "Mesothelioma", "PD-L1 Amplified Tumor (9p24.1)", "Nasopharyngeal Carcinoma" ], "interventions": [ { "name": "INCB099280", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 182, "start_date": "2020-09-04", "completion_date": "2024-11-21", "has_results": false, "last_update_posted_date": "2025-07-14", "last_synced_at": "2026-09-30T05:52:30.143Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Detroit, Michigan • Pittsburgh, Pennsylvania + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04242199" }, { "nct_id": "NCT03693612", "title": "GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "feladilimab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2018-11-26", "completion_date": "2021-09-16", "has_results": true, "last_update_posted_date": "2024-08-28", "last_synced_at": "2026-09-30T05:52:30.143Z", "location_count": 5, "location_summary": "Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03693612" } ] }